Overall market sentiment has been high on SCYNEXIS Inc (SCYX) stock lately. SCYX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
SCYNEXIS Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SCYX!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With SCYX Stock Today?
SCYNEXIS Inc (SCYX) stock has gained 9.77% while the S&P 500 is lower by -0.27% as of 1:35 PM on Monday, Nov 21. SCYX has gained $0.22 from the previous closing price of $2.27 on volume of 184,712 shares. Over the past year the S&P 500 is lower by -15.55% while SCYX is lower by -64.63%. SCYX lost -$2.18 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for SCYNEXIS Inc click here.
More About SCYNEXIS Inc
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Click Here to get the full Stock Report for SCYNEXIS Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
